Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Market Access

Set Alert for Market Access

MURANO To Drive AbbVie/Roche's Venetoclax In CLL

Top-line MURANO data support Venclexta's current conditional approvals and expand its use into a broader population that should radically boost sales.

Clinical Trials Companies Research & Development

Market Access

Set Alert for Market Access

Latest From Market Access

Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts

Pfizer filed a lawsuit against J&J over its efforts to block sales of Pfizer's biosimilar Inflectra through exclusive contracting for Remicade. The suit claims J&J coerced payers by vowing to withhold all Remicade rebates if any Inflectra is reimbursed. J&J says Pfizer has failed to show the value of Inflectra.

Biosimilars Legal Issues

Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval

Novartis got a leg up on its competition Aug. 30 with an earlier-than-expected approval for Kymriah in pediatric ALL, ending the CAR-T pricing mystery with its $475,000 price tag, which the company is positioning as a relative bargain.

Approvals Pricing Strategies

Precision Medicine: Despite Gains, Optimum Use Far From Reached

Progress has been made in areas such as lung and breast cancer, but panelists at a recent conference noted there are many efficiencies yet to be realized in drug development and reimbursement.

Personalized Medicine Market Access

Trial And Trial: Bracing For Commercialization Of Cell & Gene Therapies

As novel cell and gene therapies edge closer to the US market, reimbursement for expensive, long-lasting treatments remains uncertain. AmerisourceBergen Senior VP-Strategy & Commercialization Amy Grogg predicts the first launches will involve many different reimbursement models.

Reimbursement Market Access

The Price Is Right: Amgen Defends Repatha At $9,669 Against More Critics

Using a higher event rate typical of real-world, high-risk CV patients, Amgen asserts Repatha is cost effective at $9,669, the going discounted rate in the market. But criticism over the PCSK9 inhibitors' cost-effectiveness continues.

Pricing Strategies Cost Effectiveness

What To Look Out For At ESC, Including Merck's CETP Insights

The European Society of Cardiology meeting that starts this weekend will flesh out major studies – such as the degree of benefit seen with Merck's anacetrapib – after companies reported positive top-line results.

Clinical Trials Cardiovascular
See All